CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞疗法在 DLBCL 患者中无论有无 CNS 受累均显示相似疗效与毒性
英文原题：CAR-T Cell Therapy Shows Similar Efficacy and Toxicity in Patients With DLBCL Regardless of CNS Involvement.
查看英文原题
CAR-T Cell Therapy Shows Similar Efficacy and Toxicity in Patients With DLBCL Regardless of CNS Involvement.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
对于伴中枢神经系统（CNS）受累的复发/难治性弥漫大B细胞淋巴瘤（DLBCL），CAR-T（CAR-T）细胞疗法的疗效和毒性仍研究不足。本研究分析伴CNS受累的复发/难治性DLBCL患者接受CAR-T 治疗的结局，并与无CNS疾病患者比较。我们对接受CAR-T 治疗的复发/难治性DLBCL患者队列进行了单中心回顾性比较分析：CNS受累患者15例，无CNS受累患者65例。两队列的总体缓解率相当（均为80%；P=1.0），无进展生存期（P=0.157）和总生存期（P=0.393）亦相当。CNS组与非CNS组细胞因子释放综合征发生率相近，分别为93%和80%（P=1.0）。数值上，伴CNS表现患者的免疫效应细胞相关神经毒性综合征（所有级别）发生率较高（53%比29%；P=0.063），但未记录到4级事件。本研究提示，CAR-T 疗法对伴CNS表现的复发/难治性DLBCL患者有效且可行。
展开英文摘要原文
Efficacy and toxicity of chimeric antigen receptor T (CAR-T) cell therapy in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) with central nervous system (CNS) involvement remain understudied.
Here we analyzed the outcomes of CAR-T cell therapy in r/r DLBCL patients with CNS involvement and compared them with patients without CNS disease. Retrospective and monocentric comparative analysis of patient cohort with r/r DLBCL treated with CAR-T cell therapy: 15 patients with CNS versus 65 patients without CNS involvement.
Overall response rates (80% versus 80%; P = 1. 0), progression-free survival ( P = 0. 157), and overall survival ( P = 0. 393) were comparable for both cohorts. The frequency of cytokine release syndrome was comparable in the CNS and non-CNS cohorts; 93% versus 80%; P = 1. 0. Numerically, immune effector-cell-associated neurotoxicity syndrome (all grades) was more frequent in patients with CNS manifestation (53% versus 29%; P = 0. 063), although no grade 4 events were documented.
Our study suggests that CAR-T cell therapy is effective and feasible in patients with r/r DLBCL and CNS manifestation.
论文信息
- 作者
- Shumilov E、Boyadzhiev H、Mazzeo P、Akhoundova D、Daskalakis M、Novak U、Lenz G、Bacher U
- 第一作者单位
- Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster (UKM), Germany.Germany
- 通讯作者单位
- Department of Medical Oncology, Inselspital, University Hospital Bern, University of Bern, Switzerland.Switzerland
- 期刊
- HemaSphere2023 Dec
- 原文标识
- PubMed 38044958 · DOI 10.1097/HS9.0000000000000984
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →